retifanlimab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
primate origin 5719 2079108-44-2

Description:

MoleculeDescription

Molfile

Synonyms:

  • retifanlimab
  • retifanlimab-dlwr
  • INCMGA00012
  • MGA012
  • AEX1188
  • zynyz
Retifanlimab-dlwr binds to the PD-1 receptor, blocks interaction with its ligands PD-L1 and PD-L2, and potentiates T-cell activity. Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors, and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
March 22, 2023 FDA INCYTE CORP

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anorectal malformation 56.37 52.20 6 319 57 110588917

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FF10 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
MeSH PA D000074322 Antineoplastic Agents, Immunological
MeSH PA D000970 Antineoplastic Agents
FDA MoA N0000191259 Programmed Death Receptor-1-directed Antibody Interactions
FDA EPC N0000191260 Programmed Death Receptor-1 Blocking Antibody
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

L01FF PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors 11 drugs
atezolizumabavelumabcemiplimabdostarlimabdurvalumabnivolumabpembrolizumabserplulimabsugemalimabtislelizumabtoripalimab

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Merkel cell carcinoma indication 253001006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Programmed cell death protein 1 Membrane receptor BINDING AGENT Kd 9.22 DRUG LABEL DRUG LABEL

External reference:

IDSource
CHEBI:757460 CHEBI
CHEMBL4298037 ChEMBL_ID
C000731936 MESH_SUPPLEMENTAL_RECORD_UI
11583 IUPHAR_LIGAND_ID
DB15766 DRUGBANK_ID
4042145 VANDF
4042146 VANDF
C5401615 UMLSCUI
11095 INN_ID
365830 MMSL
41334 MMSL
d10026 MMSL
019348 NDDF
D11827 KEGG_DRUG
2Y3T5IF01Z UNII
2632980 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ZYNYZ HUMAN PRESCRIPTION DRUG LABEL 1 50881-006 INJECTION 25 mg INTRAVENOUS BLA 27 sections
ZYNYZ HUMAN PRESCRIPTION DRUG LABEL 1 50881-006 INJECTION 25 mg INTRAVENOUS BLA 27 sections